Compare ALKT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKT | IMCR |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2021 | 2016 |
| Metric | ALKT | IMCR |
|---|---|---|
| Price | $16.69 | $29.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $28.57 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 1.7M | 279.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.25 |
| Revenue | $152,159,000.00 | ★ $249,428,000.00 |
| Revenue This Year | $21.85 | $14.57 |
| Revenue Next Year | $16.90 | $8.21 |
| P/E Ratio | ★ N/A | $119.48 |
| Revenue Growth | 35.68 | ★ 43.05 |
| 52 Week Low | $14.11 | $27.56 |
| 52 Week High | $31.18 | $40.71 |
| Indicator | ALKT | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 47.22 |
| Support Level | $15.16 | $28.90 |
| Resistance Level | $17.81 | $31.56 |
| Average True Range (ATR) | 0.79 | 1.16 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 27.85 | 33.79 |
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.